Table 2.
Samplec | Pre/Post | N | Treatmentsa, b |
|||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Placebo |
Zinc Met |
ZO |
||||||||||||
Mean | SEM | 95% C.I. | Mean | SEM | 95% C.I. | Mean | SEM | 95% CI |
||||||
Lower | Upper | |||||||||||||
Fecal zinc | Pre | 71 | 135.9 A | 17.0 | 100.9 | 171.0 | 153.6 A | 21.9 | 108.5 | 198.8 | 153.0 A | 14.1 | 123.6 | 182.3 |
Post | 71 | 378.4 A | 48.2 | 278.4 | 478.5 | 1128.9 B | 255.5 | 601.5 | 1656.3 | 651.3 AB | 53.4 | 540.5 | 762.0 | |
Serum zinc | Pre | 71 | 0.95 A | 0.04 | 0.87 | 1.03 | 0.91 A | 0.04 | 0.82 | 1.00 | 0.91 A | 0.07 | 0.76 | 1.05 |
Post | 71 | 1.09 A | 0.05 | 0.99 | 1.19 | 1.28 B | 0.05 | 1.18 | 1.39 | 1.16 AB | 0.05 | 1.05 | 1.26 | |
Liver zincd | Pre | 71 | 710.6 A | 147.7 | 405.2 | 1016.1 | 852.3 A | 129.6 | 585.4 | 1119.1 | 750.7 A | 202.9 | 327.5 | 1173.9 |
Post | 68 | 728.9 A | 182.9 | 349.6 | 1108.3 | 1141.0 A | 423.8 | 264.2 | 2017.7 | 636.8 A | 81.5 | 466.9 | 806.8 | |
Liver copper | Pre | 73 | 483.9 A | 51.3 | 378.1 | 589.8 | 500.4 A | 68.9 | 358.6 | 642.3 | 477.3 A | 59.8 | 353.0 | 601.6 |
Post | 70 | 683.0 A | 119.7 | 435.3 | 930.7 | 741.7 A | 211.5 | 304.2 | 1179.1 | 468.1 A | 63.5 | 336.1 | 600.0 | |
Liver irond | Pre | 71 | 381.7 A | 72.4 | 232.2 | 531.2 | 363.3 A | 65.9 | 227.6 | 499.1 | 205.9 A | 33.3 | 136.3 | 275.5 |
Post | 68 | 347.3 A | 90.6 | 159.9 | 534.6 | 254.1 A | 46.5 | 157.9 | 350.3 | 157.7 A | 24.4 | 106.7 | 208.8 |
Treatments: Placebo = zinc-free oral rehydration solution (ORS); zinc Met = 80 mg of zinc/2 L of ORS (381.5 mg of zinc Met); ZO = 80 mg of zinc/2 L of ORS (99.7 mg of ZO).
Means with different letters within each row are significantly different (P < 0.05).
Fecal zinc (mg/kg of DW), serum zinc (mg/L), and liver zinc, copper, and iron (mg/kg of DW).
Liver zinc and iron concentration pre and post treatment: liver biopsy samples were insufficient for accurate zinc or iron determination in two samples. Thus, two calves had to be excluded from liver zinc and iron enrollment and exit analysis.